celltrion inc -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- initi coverag under-perform
innov biosimilar develop race
celltrion inc pure player develop manufactur
biosimilar market three biosimilar europ one
biosimilar us first-mov inflectra remicad
biosimilar uptak us may find inflect point
believ us favour adopt biosimilar
celltrion inc plan introduc subcutan sc version
remsima incept sc version allow celltrion
inc penetr humira enbrel market combin
us sale patent protect us
discourag lack biosimilar approv pathway
deter launch remsima sc us could launch
novel biolog pathway dilut econom
valu increas cost delay launch separ brand
initi coverag under-perform rate given
demand valuat target price
deriv blend dcf target price-to-earnings methodolog
mix order captur long-term growth potenti near-
estimate pot chg tp
 chang prev ep
note celltrion inc develop manufactur biolog product chemic drug well
consign process servic compani special develop biosimilar
rheumatoid athrithi blood cancer breast cancer
click detail financi
first-mov major market celltrion inc pure player
develop manufactur biosimilar market three
biosimilar remsima truxima herzuma europ
one biosimilar us inflectra first-mov
market forecast enjoy healthi growth on-going
biosimilar uptak product launch
largest beneficiari like us tailwind inflectra
remicad biosimilar uptak us may find inflect point
believ us favour adopt biosimilar
recent regulatori progress j-code inclus could overwhelm
penetr bn us remicad market
figur celltrion inc claim first-mov major biosimilar market
sale compani data credit suiss estim
approv risk remsima sc launch celltrion inc move
quickli biobett product plan introduc subcutan
sc version remsima remicad biosimilar
incept sc version allow penetr humira
enbrel market combin us sale bn
patent protect us respect
howev discourag lack biosimilar approv pathway
deter launch remsima sc us could launch
novel biolog pathway dilut econom valu
remsima sc due increas clinic trial cost delay launch
result limit penetr separ brand
valuat look unjustifi given uncertainti remsima
initi coverag
under-perform rate given demand valuat
tp deriv blend dcf target price-to-earnings
methodolog mix order captur long-term growth
potenti near-term earn momentum risk includ
favour approv guidelin remsima sc faster-than-
novel biolog candid overal industri
adj prob
figur remsima sc valu per share upsid potenti unit krw
eu/u
prob
fair valu
figur celltrionconsensu valuat sinc ipo celltrion hc
seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid
report singl factor make invest decis
compani mention price
ray certifi view express report accur reflect person view subject compani secur
part compens directli indirectli relat specif recommend view express report
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attractiv neutral less attract
underperform least attract invest opportun octob canadian well european rate base stock total return
rel analyst coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun latin american asia stock exclud japan
australia rate base stock total return rel aver age total return relev countri region benchmark india bse sensex index
prior octob canadian rate base stock absolut total return potenti curren share price rel
attract stock total return potenti within analyst coverag univers australian new zealand stock expect total return calcul
includ roll dividend yield outperform rate assign greater equal under-perform less
equal neutral may assign overlap rate rang allow analyst assign rate put
context associ risk prior may rang outperform under-perform rate overlap neutral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
rate nr credit suiss equiti research invest rate view stock secur relat compani
time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate invest view
equiti secur compani relat product
volatil indic stock defin volatil stock price move month least past
month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or valuat
sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sect analyst may cover multipl sector
credit suiss distribut stock rate bank client
bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral nd under-perform close correspond
